0000000001327860
AUTHOR
Manuela Lopez
Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study
GRUPPO ONCOLOGICO ITALIA MERIDIONALE. NOVEL ASSOCIATION WITH GEMCITABINE AND DOCETAXEL AS SALVAGE CHEMOTHERAPY IN METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ANTHRACYCLINES: RESULT OF A NULTICENTER PHASE II STUDY
Submarine volcanism in the Sicily Channel: the messagge from a deep mantle reservoir.
Submarine volcanism in the Sicily Channel Rift: new data from Graham, Nameless and Pantelleria Banks
“Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer:the IGCS-COL multicentre, randomised, phase III study”
The aims of this multicentre, randomised phase III trial were to evaluate: (1) the role of levamisol (LEV); and (2) the role of folinic acid (FA), added to 5-fluorouracil (5FU) in the adjuvant treatment of colorectal cancer. Patients with histologically proven, radically resected stage II or III colon or rectal cancer were eligible. The study had a 2x2 factorial design with four treatment arms: (a) 5FU alone, (b) 5FU+LEV, (c) 5FU+FA, (d) 5FU+LEV+FA, and two planned comparisons, testing the role of LEV and of FA, respectively. From March 1991, to September 1998, 1327 patients were randomised. None of the two comparisons resulted in a significant disease-free (DFS) or overall (OAS) survival a…
Epirubicina (EPI ) e Docetaxel (DOC ) come chemioterapia primaria ( C P ) nel trattamento del carcinoma mammario localmente avanzato ( CMLA ). VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004
FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale
European contribution to the study of ROS : A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)
WOS: 000410470000009